Oncotarget

Clinical Research Papers:

Combination of platelet count and lymphocyte to monocyte ratio is a prognostic factor in patients undergoing surgery for non-small cell lung cancer

Wei Liu, Minwen Ha and Nanchang Yin _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:73198-73207. https://doi.org/10.18632/oncotarget.18336

Metrics: PDF 1658 views  |   HTML 2723 views  |   ?  


Abstract

Wei Liu1, Minwen Ha1 and Nanchang Yin2

1 Department of Medical Oncology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China

2 Department of Thoracic Surgery, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China

Correspondence to:

Nanchang Yin, email:

Keywords: platelet count, lymphocyte to monocyte ratio, non-small cell lung cancer, prognosis

Received: December 23, 2016 Accepted: May 15, 2017 Published: June 01, 2017

Abstract

The aim of this study was to investigate the usefulness of a novel inflammation-based prognostic system, called COP-LMR (combination of platelet count and lymphocyte to monocyte ratio), for predicting postoperative survival of patients with non-small cell lung cancer (NSCLC). COP-LMR was calculated on the basis of the obtained data. Patients with both an elevated platelet count (PLT) (>30 × 104mm-3) and a low LMR (<3.6) were assigned a score of 2, and patients with one or none of the parameters were assigned a score of 1 or 0, respectively. A total of 1120 patients who underwent complete resection were enrolled in this study. Multivariate analysis revealed that COP-LMR is an independent prognostic factor for disease-free survival (DFS) (P<0.001) and overall survival (OS) (P<0.001). Kaplan-Meier analysis and the log-rank test revealed that COP-LMR stratified the patients into 3 independent groups (P<0.001). In conclusion, COP-LMR is a potential prognostic biomarker in patients undergoing surgery for NSCLC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 18336